Author: admin

“Postpartum Depression market growth”

The Postpartum Depression market report also offers comprehensive insights into the Postpartum Depression market size, share, Postpartum Depression epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Postpartum Depression market size growth forward.

Some of the key highlights from the Postpartum Depression Market Insights Report:

• Several key pharmaceutical companies, including Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others, are developing novel products to improve the Postpartum Depression treatment outlook.

• In February 2024, the US Department of Health and Human Services (HHS), along with HHS leaders, engaged with state officials and the National Governors Association (NGA) to announce the launch of the HHS Secretary’s Postpartum Maternal Health Collaborative. This initiative aims to enhance maternal and child health in rural America.

• In December 2023, the Centers for Medicare & Medicaid Services introduced the new Transforming Maternal Health (TMaH) Model. This model focuses on improving access to care, building infrastructure and workforce capacity, enhancing quality and safety, and promoting whole-person care delivery.

• In August 2023, the American Psychiatric Association released new educational resources on maternal mental health. These resources include a toolkit with eight fact sheets for both clinicians and patients, a white paper, and a four-part webinar series addressing this often overlooked area of mental health.

• The Postpartum Depression (PPD) treatment market in the 7MM was valued at USD 260 million in 2023. Among the EU4 and the UK, the UK had the highest market size for PPD, reaching approximately USD 25 million in 2023. Across the seven major markets, there were around 1,310,000 diagnosed prevalent cases of Postpartum Depression in 2023, with about 460,000 of these cases occurring in females in the EU4 and the UK.

• Postpartum Depression is the most common non-psychotic complication affecting women after childbirth, potentially disrupting maternal-infant bonding and negatively impacting both immediate and long-term child development. It is diagnosed when at least five depressive symptoms persist for two or more weeks. According to the DSM-5, PPD is identified as a major depressive episode with peripartum onset, though it is not listed as a separate disorder.

• Screening for PPD is typically conducted 2 to 6 months postpartum, with women also assessed for manic symptoms. The Edinburgh Postnatal Depression Scale (EPDS) is one of the most widely used screening tools. Selective serotonin reuptake inhibitors (SSRIs) are the primary treatment choice, and a combination of antidepressants and therapy is recommended for moderate to severe cases.

• ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) are the only FDA-approved treatments for PPD. Zulresso is administered via continuous intravenous infusion, while ZURZUVAE is taken orally for 14 days at a dosage of 50 mg. Key players in the development of new PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

• Several major companies are leading the Postpartum Depression treatment landscape, including Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, Brii Biosciences, and others. Below are the details of the Postpartum Depression market size by country and therapy.

• The Postpartum Depression treatment market in the 7MM was valued at approximately USD 260 million in 2023. In the seven major markets for Postpartum Depression therapeutics, SNRIs and SSRIs accounted for 20% of the overall market share, while atypical antidepressants and antipsychotics held a 19% share in 2023.

• By 2034, ZURZUVAE is projected to generate around USD 600 million in revenue from the Postpartum Depression therapeutics market in the 7MM.

• As per DelveInsight analysis, the Postpartum Depression market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Postpartum Depression Market Landscape

Postpartum Depression Overview

Postpartum depression (PPD) is the most prevalent non-psychotic complication during the childbearing period, affecting about 10-15% of women, and represents a significant public health issue impacting both women and their families. The postnatal period is widely recognized as a time of increased vulnerability for developing severe mood disorders. There are three main types of postpartum mood disorders: the baby blues (maternity blues), postpartum depression, and puerperal psychosis, each varying in prevalence, clinical symptoms, and treatment. The impact of postnatal depression on the mother, her relationship with her partner, and her children makes it crucial to diagnose, treat, and prevent this condition. If left untreated, PPD can lead to long-term negative effects, including chronic recurrent depression in the mother and emotional, behavioral, cognitive, and social issues in her children.

The link between the postpartum period and mood disturbances has been recognized since the time of Hippocrates. Research shows that women are at an increased risk of severe psychiatric conditions during the puerperium. In fact, studies indicate that women are more likely to be admitted to psychiatric hospitals in the first month after childbirth than at any other time. Approximately 12.5% of all psychiatric hospital admissions for women occur during the postpartum period.

Do you know the treatment paradigms for different countries? Download our Postpartum Depression Market Sample Report

Postpartum Depression Epidemiology Segmentation

DelveInsight’s Postpartum Depression market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Postpartum Depression historical patient pools and forecasted Postpartum Depression patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Postpartum Depression Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Postpartum Depression Prevalence

• Age-Specific Postpartum Depression Prevalence

• Gender-Specific Postpartum Depression Prevalence

• Diagnosed and Treatable Cases of Postpartum Depression

Visit for more @ Postpartum Depression Epidemiological Insights

Postpartum Depression Market Outlook

Antidepressants such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) are central to the treatment of Postpartum Depression (PPD). While these medications are approved for conditions like major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and treatment-resistant depression (TRD), they are commonly used off-label for PPD. The choice of medication largely depends on the symptoms, severity, and specific type of PPD the patient is experiencing. A key concern with antidepressants is the uncertain outcomes and potential side effects on newborns due to breastfeeding. Although antidepressants do not offer a permanent cure for PPD, they play a crucial role in managing depressive symptoms and improving the quality of life.

New therapies with innovative mechanisms, such as GABAA receptor positive allosteric modulators and allosteric modulators of the GABA receptor, are being developed by companies like Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences for PPD treatment.

In conclusion, despite the current lack of adequate treatments for Postpartum Depression, many promising therapies with novel mechanisms are expected to enter the market, addressing a significant unmet need in PPD care and greatly improving treatment outcomes. As new treatment options become available and healthcare spending increases across the 7MM, the Postpartum Depression treatment market is projected to experience substantial growth during the forecast period (2024–2034).

Postpartum Depression Marketed Drugs

• ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen

• ZULRESSO: Sage Therapeutics

Postpartum Depression Emerging Drugs

• Ganaxolone: Marinus Pharmaceuticals

Postpartum Depression Key Companies

• Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others

For more information, visit Postpartum Depression Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Postpartum Depression Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Postpartum Depression, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Postpartum Depression epidemiology in the 7MM

• Postpartum Depression marketed and emerging therapies

• Postpartum Depression companies

• Postpartum Depression market drivers and barriers

Table of Contents:

1 Postpartum Depression Market Key Comprehensive Insights

2 Postpartum Depression Market Report Introduction

3 Competitive Intelligence Analysis for Postpartum Depression

4 Postpartum Depression Market Analysis Overview at a Glance

5 Executive Summary of Postpartum Depression

6 Postpartum Depression Epidemiology and Market Methodology

7 Postpartum Depression Epidemiology and Patient Population

8 Postpartum Depression Patient Journey

9 Postpartum Depression Treatment Algorithm, Postpartum Depression Current Treatment, and Medical Practices

10 Key Endpoints in Postpartum Depression Clinical Trials

11 Postpartum Depression Marketed Therapies

12 Postpartum Depression Emerging Therapies

13 Postpartum Depression: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Postpartum Depression

16 Postpartum Depression Market Key Opinion Leaders Reviews

18 Postpartum Depression Market Drivers

19 Postpartum Depression Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Postpartum Depression Epidemiology 2034

DelveInsight’s “Postpartum Depression – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Postpartum Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Postpartum Depression Pipeline 2024

“Postpartum Depression Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Postpartum Depression market. A detailed picture of the Postpartum Depression pipeline landscape is provided, which includes the disease overview and Postpartum Depression treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market

“Burn pain Market 2034”

The Burn pain market report also offers comprehensive insights into the Burn pain market size, share, Burn pain epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Burn pain market size growth forward.

Some of the key highlights from the Burn pain Market Insights Report:

• Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Burn pain treatment outlook.

• In 2018, the U.S. Food and Drug Administration (FDA) approved the ReCell Autologous Cell Harvesting Device for treating burn injuries. This device enables clinicians to use small samples of a patient’s own cells to treat wounds and skin defects. The procedure is performed on-site at the bedside, takes approximately 25 minutes to complete, and does not require laboratory facilities, off-site tissue culture, or specialized staff. ReCell is approved in Europe, the Middle East, Africa (EMEA), and Australia, and is undergoing clinical trials in the U.S. for burns and scars.

• The United States, which has the highest number of treated incident cases of burn pain, also holds the largest market share among the 7MM countries and is expected to maintain this dominance throughout the forecast period (2024–2034).

• In the 7MM, burn pain cases are more prevalent among males than females, largely due to factors such as occupational hazards. Men are disproportionately represented in high-risk professions like firefighting and industrial work, contributing to this disparity.

• In the United States, flame-related incidents account for a greater number of etiology-specific burn cases compared to other causes. According to DelveInsight’s analysis, these cases are categorized by cause, including flame, contact, scald, electrical, chemical, and others.

• Across the 7MM, second-degree burns represent the majority of severity-specific burn incidents, surpassing first-degree, third-degree, and unspecified cases. This is likely due to the deeper tissue involvement and higher risk of complications associated with second-degree burns.

• As per DelveInsight analysis, the Burn pain market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Burn pain Market Landscape

Burn pain Overview

Burns are injuries to the skin or other tissues caused by heat, radiation, electricity, chemicals, friction, or other factors. Burn pain arises from damage to peripheral sensory neurons and inflammatory processes, resulting in complex symptoms such as persistent background pain and procedural pain during treatment. Symptoms vary based on the burn’s depth, ranging from redness and pain in first-degree burns to swelling and discoloration in second-degree burns, and tissue destruction with numbness in third-degree burns. Beyond the affected area, burn injuries can have both local and systemic effects, impacting other organs and systems. These injuries carry physical, psychological, and socioeconomic implications, requiring prompt, interdisciplinary management to mitigate adverse effects and support recovery.

Diagnosing burn pain involves a clinical evaluation of the burn’s nature, depth, and severity, alongside the patient’s reported symptoms. Diagnostic processes often include assessing for complications such as infections or nerve damage and determining the appropriate treatment plan. However, challenges in diagnosis may stem from individual differences in pain perception, difficulties in accurately gauging pain severity, and the subjective nature of pain reporting. Additionally, underlying conditions or comorbidities may further complicate diagnosis. Despite these limitations, a thorough evaluation by healthcare professionals is critical for guiding effective burn pain management strategies.

Managing burn pain is particularly challenging due to its intensity and duration, often requiring a multifaceted approach. Severe acute pain is initially treated with potent opioids and local anesthetics. As acute pain subsides, these are gradually replaced with less potent oral opioids and peripheral-acting medications. Eventually, pain management may rely solely on peripherally-acting drugs such as aspirin or NSAIDs. Multimodal analgesia, with careful dose adjustments to balance pain relief and side effects, is essential for effective treatment. Continuous pain assessment and monitoring of treatment responses are vital to optimizing patient outcomes and quality of life.

Do you know the treatment paradigms for different countries? Download our Burn pain Market Sample Report

Burn pain Epidemiology Insights

• In 2023, the United States recorded over 2 million incident burn cases, a number projected to rise by 2034. Among these, approximately 0.4 million cases required pain management therapies, with this figure expected to shift during the study period from 2020 to 2034.

• The gender distribution across the 7MM indicates a higher prevalence among males. In the US alone, there were an estimated 0.29 million cases in males compared to 0.26 million in females in 2023.

Burn pain Epidemiology Segmentation

DelveInsight’s Burn pain market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Burn pain historical patient pools and forecasted Burn pain patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Burn pain Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Burn pain Prevalence

• Age-Specific Burn pain Prevalence

• Gender-Specific Burn pain Prevalence

• Diagnosed and Treatable Cases of Burn pain

Visit for more @ Burn pain Epidemiological Insights

Burn pain Market Insights:

• In 2023, the US maintained the largest market share among the 7MM, valued at USD 140 million. Projections indicate that this trend will persist, with the US expected to continue expanding its market presence and maintain its leading position by 2034.

• In 2023, Germany and the UK in the EU4 and the UK each captured a market share exceeding USD 20 million, closely followed by France. In contrast, Italy recorded the smallest market share among these regions during the same period.

Burn pain Market Outlook

Burn pain, known for its intensity and prolonged nature, presents significant challenges in management due to its complex characteristics and diverse components. The goal of burn therapy is to effectively and safely relieve pain, reduce complications and side effects, maintain the patient’s functional ability, and improve overall quality of life.

In the initial stages, severe acute burn pain is typically managed with strong opioids and local anesthesia. As the acute pain decreases, injectable pain relief is gradually reduced and replaced with less potent oral opioids and medications targeting the peripheral nervous system. Ultimately, pain control often relies on peripherally acting drugs like aspirin or NSAIDs. A key aspect of successful treatment is multimodal analgesia, where dosages are adjusted to balance optimal pain relief with minimal side effects. Continuous and detailed monitoring of pain and treatment effectiveness is crucial.

Beyond pharmacological approaches, effective pain management for burn patients involves a multidisciplinary strategy. This approach includes collaboration among psychologists, psychotherapists, physical therapists, and pain specialists to address the multifaceted nature of burn pain and its broader impact on patients’ well-being.

In the current market, off-label medications dominate, while the burn pain pipeline remains notably underdeveloped. This presents an opportunity for pharmaceutical companies to invest in research aimed at developing innovative drugs with new mechanisms of action, providing more effective and convenient treatment options tailored to the needs of burn pain patients.

Burn pain Marketed Drugs

The treatment market for burn pain in the United States currently lacks approved therapies, creating a significant opportunity for key players to explore in the development of burn pain treatments within the US market.

Meanwhile, Penthrox, developed by Medical Developments International, has recently received approval in Europe, Latin America, and South Africa for providing emergency relief for moderate to severe pain in conscious adult patients suffering from trauma-related pain.

Burn pain Emerging Drugs

Given the current market situation, where off-label medications are prevalent and the burn pain pipeline lacks effective therapies, pharmaceutical companies have a valuable opportunity to invest in research focused on developing new drugs with innovative mechanisms of action. These medications could provide more convenient and effective treatment options specifically designed to address the needs of patients experiencing burn pain.

Burn pain Key Companies

• ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others

For more information, visit Burn pain Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Burn pain Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Burn pain, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Burn pain epidemiology in the 7MM

• Burn pain marketed and emerging therapies

• Burn pain companies

• Burn pain market drivers and barriers

Table of Contents:

1 Burn pain Market Key Comprehensive Insights

2 Burn pain Market Report Introduction

3 Competitive Intelligence Analysis for Burn pain

4 Burn pain Market Analysis Overview at a Glance

5 Executive Summary of Burn pain

6 Burn pain Epidemiology and Market Methodology

7 Burn pain Epidemiology and Patient Population

8 Burn pain Patient Journey

9 Burn pain Treatment Algorithm, Burn pain Current Treatment, and Medical Practices

10 Key Endpoints in Burn pain Clinical Trials

11 Burn pain Marketed Therapies

12 Burn pain Emerging Therapies

13 Burn pain: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Burn pain

16 Burn pain Market Key Opinion Leaders Reviews

18 Burn pain Market Drivers

19 Burn pain Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Burn pain Epidemiology 2034

DelveInsight’s “Burn pain – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Burn pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Burn pain Pipeline 2024

“Burn pain Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Burn pain market. A detailed picture of the Burn pain pipeline landscape is provided, which includes the disease overview and Burn pain treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Burn pain Market Expected to rise, 2034 | Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Lifescience Pvt. Ltd, 3M

“Wilson’s Disease Market 2034”

The Wilson’s Disease market report also offers comprehensive insights into the Wilson’s Disease market size, share, Wilson’s Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Wilson’s Disease market size growth forward.

Some of the key highlights from the Wilson’s Disease Market Insights Report:

• Several key pharmaceutical companies, including Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, and others, are developing novel products to improve the Wilson’s Disease treatment outlook.

• In January 2025, Eton Pharmaceuticals, Inc., announced that Galzin is an FDA-approved treatment for Wilson Disease, an ultra-rare metabolic disorder.

• According to DelveInsight’s estimates, there were approximately 8,000 diagnosed prevalent cases of Wilson’s disease across the 7MM in 2023. These cases are expected to rise during the forecast period (2024–2034).

• In 2023, the market for Wilson’s Disease was the largest in the US within the 7MM, valued at around USD 126 million, with expectations for a 13% compound annual growth rate (CAGR) over the forecast period.

• Current treatment options primarily include Chelating agents (D-penicillamine, trientine), Zinc Salts, and others. Chelating agents accounted for the largest share of the market, reaching approximately USD 123 million in 2023 for Wilson’s Disease treatment in the US.

• In May 2022, the US FDA approved Orphalan’s CUVRIOR (trientine tetrahydrochloride) for treating adults with stable Wilson’s disease who are decoupled and tolerant to penicillamine.

• The Wilson’s Disease treatment market in the 7MM is driven by factors such as increasing awareness, early diagnosis, advances in genetic testing, and ongoing research into new therapies. Rising prevalence, along with greater healthcare investments in rare diseases, further contributes to market growth. Additionally, patient advocacy efforts are helping to improve treatment options and expand the market.

• The US FDA has also granted Fast Track designation to VTX-801, a gene therapy from Vivet currently in clinical development for Wilson’s Disease. This designation is part of the FDA’s Fast Track program, aimed at expediting the development and review of innovative treatments for serious conditions with unmet medical needs.

• As per DelveInsight analysis, the Wilson’s Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Wilson’s Disease Market Landscape

Wilson’s Disease Overview

According to the European Association for the Study of the Liver (EASL), Wilson’s disease is a genetic disorder characterized by impaired biliary copper excretion, leading to its accumulation, particularly in the liver and brain.

The condition is progressive, and if untreated, it can result in liver disease, central nervous system dysfunction, and even death. Early detection and treatment can help prevent severe long-term disability and life-threatening complications. Wilson’s disease typically presents with a combination of liver, neurological, and psychiatric symptoms. In children and young adults, liver disease is often the first sign, whereas individuals diagnosed later in life may not exhibit obvious liver symptoms, though mild liver disease may still be present. Symptoms of liver disease include jaundice (yellowing of the skin or eyes), fatigue, loss of appetite, and abdominal swelling. In adults, neurological or psychiatric symptoms are often the first to appear, and they are common in young adults with the condition. These symptoms may include clumsiness, tremors, difficulty walking, speech issues, cognitive impairment, depression, anxiety, and mood swings. Wilson’s disease is caused by a mutation in the ATP7B gene, which is responsible for copper transport. The disease occurs when an individual inherits the mutated gene from both parents.

Do you know the treatment paradigms for different countries? Download our Wilson’s Disease Market Sample Report

Wilson’s Disease Epidemiology Insights

• In 2023, there were around 37,000 prevalent cases of Wilson’s Disease across the 7MM, yet the treatment market for the condition lacks therapies specifically approved for its management. According to the analysis, the United States recorded the highest number of diagnosed prevalent cases, with approximately 2,600, followed by Japan with nearly 2,200 cases. Conversely, Spain had the fewest diagnosed prevalent cases, totaling approximately 300.

Wilson’s Disease Epidemiology Segmentation

DelveInsight’s Wilson’s Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Wilson’s Disease historical patient pools and forecasted Wilson’s Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Wilson’s Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Wilson’s Disease Prevalence

• Age-Specific Wilson’s Disease Prevalence

• Gender-Specific Wilson’s Disease Prevalence

• Diagnosed and Treatable Cases of Wilson’s Disease

Visit for more @ Wilson’s Disease Epidemiological Insights

Wilson’s Disease Market Insights:

• In 2023, the therapeutic market for Wilson’s Disease in the 7MM was valued at approximately USD 295 million. The market is projected to grow at a CAGR of 12%, driven by increased disease awareness, improved diagnostic capabilities, and the introduction of emerging therapies.

• Among the 7MM, the United States represented the largest market share, accounting for roughly 43% of the total market in 2023. This was significantly higher compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Wilson’s Disease Market Outlook

Several medications are available for treating Wilson’s disease, including D-penicillamine, trientine, zinc, tetrathiomolybdate, and dimercaprol. Once diagnosed, lifelong treatment is necessary.

Treatment options fall into three categories:

1. Chelating agents: These medications remove copper from the body via urinary excretion. Examples include penicillamine (CUPRIMINE) and trientine dihydrochloride (SYPRINE).

2. Zinc salts: These prevent the absorption of dietary copper in the gut. Zinc acetate is preferred due to its superior gastric tolerance.

3. Tetrathiomolybdate: This dual-action drug blocks copper absorption and binds toxic copper in the bloodstream, rendering it harmless.

Key Treatment Details:

• Trientine: Developed in 1969 as an alternative for patients intolerant to D-penicillamine, trientine promotes copper excretion through urine. The recommended dose ranges from 750–1500 mg/day in divided doses, with a maintenance dose of 750–1000 mg/day.

• D-penicillamine: Introduced in 1956 as the first oral treatment, it chelates copper and facilitates its excretion via urine. Co-administration with pyridoxine (25–50 mg daily) is recommended to prevent vitamin B6 deficiency. Hepatic function typically improves within 2–6 months. Dosage begins at 250–500 mg/day, increasing by 250 mg every 4–7 days to a maximum of 1–1.5 g/day, divided into multiple doses.

• Zinc salts: First used in the 1960s, zinc salts (like zinc acetate) promote copper elimination through feces by inducing metallothionein in enterocytes. This helps normalize copper levels in the blood.

• Tetrathiomolybdate (TTM): Used in Europe since 2008, TTM promotes copper excretion via urine and feces and is particularly effective for severe neurological symptoms. Common side effects include elevated liver enzymes and bone marrow suppression. TTM is not yet FDA-approved in the United States.

Emerging Treatments:

Several new drugs are under development for Wilson’s disease, including VTX-801 by Vivet Therapeutics and UX701 by Ultragenyx Pharmaceutical. These agents aim to offer improved treatment options for this challenging condition.

Wilson’s Disease Marketed Drugs

• CUVRIOR/CUPRIOR (trientine tetrahydrochloride): Orphalan

Wilson’s Disease Emerging Drugs

• VTX-801: Vivet Therapeutics

• UX701: Ultragenyx Pharmaceutical

Wilson’s Disease Key Companies

• Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, and others

For more information, visit Wilson’s Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Wilson’s Disease Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Wilson’s Disease, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Wilson’s Disease epidemiology in the 7MM

• Wilson’s Disease marketed and emerging therapies

• Wilson’s Disease companies

• Wilson’s Disease market drivers and barriers

Table of Contents:

1 Wilson’s Disease Market Key Comprehensive Insights

2 Wilson’s Disease Market Report Introduction

3 Competitive Intelligence Analysis for Wilson’s Disease

4 Wilson’s Disease Market Analysis Overview at a Glance

5 Executive Summary of Wilson’s Disease

6 Wilson’s Disease Epidemiology and Market Methodology

7 Wilson’s Disease Epidemiology and Patient Population

8 Wilson’s Disease Patient Journey

9 Wilson’s Disease Treatment Algorithm, Wilson’s Disease Current Treatment, and Medical Practices

10 Key Endpoints in Wilson’s Disease Clinical Trials

11 Wilson’s Disease Marketed Therapies

12 Wilson’s Disease Emerging Therapies

13 Wilson’s Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Wilson’s Disease

16 Wilson’s Disease Market Key Opinion Leaders Reviews

18 Wilson’s Disease Market Drivers

19 Wilson’s Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Wilson’s Disease Epidemiology 2034

DelveInsight’s “Wilson’s Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Wilson’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Wilson’s Disease Pipeline 2024

“Wilson’s Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Wilson’s Disease market. A detailed picture of the Wilson’s Disease pipeline landscape is provided, which includes the disease overview and Wilson’s Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market

“Onychomycosis Market 2034”

The Onychomycosis market report also offers comprehensive insights into the Onychomycosis market size, share, Onychomycosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Onychomycosis market size growth forward.

Some of the key highlights from the Onychomycosis Market Insights Report:

• Several key pharmaceutical companies, including Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others, are developing novel products to improve the Onychomycosis treatment outlook.

• In June 2014, the FDA approved JUBLIA for treating toenail onychomycosis caused by *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

• In July 2014, CLENAFIN (efinaconazole) received approval from the PMDA for the treatment of onychomycosis in Japan.

• In 2023, there were approximately 83,553 thousand prevalent cases of Onychomycosis across the 7MM. The rise in cases can be attributed to factors such as aging populations, lifestyle habits like poor foot hygiene and tight footwear, and increased exposure to communal areas such as swimming pools, which heighten susceptibility.

• According to DelveInsight’s analysts, in 2023, distal subungual onychomycosis was the most common subtype of Onychomycosis in the US, accounting for approximately 90% of cases. There were 6,034 thousand cases of this subtype in 2023, with projections indicating changes throughout the study period (2020-2034).

• Among the EU4 and the UK, France had the highest number of diagnosed prevalent Onychomycosis cases, with about 2,046 thousand cases in 2023, and these numbers are expected to change during the study period (2020-2034).

• Onychomycosis is typically categorized into mild (25% or less nail involvement), moderate (26–74% involvement), and severe (more than 75% involvement). In 2023, Spain had 70,300 mild, 101,630 moderate, and 82,781 severe cases. DelveInsight’s analysis predicts an increase in these cases during the forecast period (2024-2034).

• Among the approved treatments for Onychomycosis, Topical Pharmacotherapy is projected to hold the largest market share in the US by 2034.

• With the anticipated approval of new therapies during the forecast period (2024–2034), the Onychomycosis therapeutic market is expected to grow significantly at a strong CAGR. This growth will likely be driven by enhanced diagnostic methods, the introduction of new products, and ongoing research into pharmaceutical treatments.

• As per DelveInsight analysis, the Onychomycosis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Onychomycosis Market Landscape

Onychomycosis Overview

Onychomycosis, a fungal infection of the nail, is the most prevalent nail infection globally, leading to discoloration and thickening of the affected nail. Initially believed to be primarily caused by dermatophytes, recent studies have shown that mixed infections and those caused by non-dermatophyte molds (NDMs) are more common, particularly in warmer climates. When caused by dermatophytes, onychomycosis is referred to as tinea unguium. The term onychomycosis includes not only dermatophyte infections but also those caused by yeasts and saprophytic molds. While onychomycosis can affect both fingernails and toenails, toenail infections are far more common. An abnormal nail not caused by a fungal infection is termed a dystrophic nail.

Onychomycosis is traditionally classified into subtypes based on how the fungus invades the nail, which helps guide treatment. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal part of the nail plate. In superficial white onychomycosis (SWO), the fungus affects the surface layers of the nail plate. Proximal subungual onychomycosis (PSO) happens when the infection begins at the undersurface of the proximal nail fold and spreads distally. Endonyx onychomycosis (EO) involves the fungus invading the nail plate without affecting the nail bed. Total dystrophic onychomycosis (TDO) represents advanced onychomycosis and may follow any of the other subtypes. Secondary onychomycosis (SO) is a non-fungal nail condition (e.g., psoriasis) that becomes infected with a secondary fungal infection, showing characteristics of both fungal and non-fungal nail disorders.

Do you know the treatment paradigms for different countries? Download our Onychomycosis Market Sample Report

Onychomycosis Epidemiology Insights

• In 2023, the total number of prevalent onychomycosis cases in the US was approximately 37,250 thousand. This figure is expected to undergo significant changes by 2034.

• In Germany, during 2023, moderate onychomycosis cases were the most common, with around 726 thousand reported. These numbers are anticipated to vary throughout the forecast period from 2024 to 2034.

Onychomycosis Epidemiology Segmentation

DelveInsight’s Onychomycosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Onychomycosis historical patient pools and forecasted Onychomycosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Onychomycosis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Onychomycosis Prevalence

• Age-Specific Onychomycosis Prevalence

• Gender-Specific Onychomycosis Prevalence

• Diagnosed and Treatable Cases of Onychomycosis

Visit for more @ Onychomycosis Epidemiological Insights

Onychomycosis Market Outlook

Onychomycosis is mainly a fungal infection of the nail bed, commonly known as ‘toenail fungus’ since toenail infections account for the majority of cases. Toenail issues are among the most common foot problems prompting adults to seek both over-the-counter treatments and professional care. The infection usually starts as a small white or yellow spot beneath the nail plate, leading to discoloration, thickening, and splitting of the nail. It is estimated that onychomycosis affects about 3% of the general adult population, with approximately 20% of individuals aged 40 to 60 years affected.

The current treatment options are typically categorized by their method of administration: Systemic (oral) and Topical medications.

Despite numerous attempts to develop effective treatments for toenail fungus, the few FDA/EMA/PMDA-approved products currently available remain suboptimal for two key reasons. Topical treatments often have low cure rates and poor efficacy since they cannot penetrate the nail plate adequately to reach the infected nail bed, and they may require nail debridement before application. On the other hand, the leading oral medication, terbinafine, must be taken daily for three months, and its systemic presence can lead to adverse effects. Both treatment types have low cure rates, with hepatotoxicity being a common side effect from prolonged oral use. Patients taking terbinafine must undergo regular liver function tests to monitor potential damage.

Onychomycosis Marketed Drugs

• KERYDIN (tavaborole): Pfizer

• JUBLIA/CLENAFIN (efinaconazole): Bausch Health

Onychomycosis Emerging Drugs

• BB2603: Blueberry Therapeutics

• VT-1161: Mycovia Pharmaceuticals

Onychomycosis Key Companies

• Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others

For more information, visit Onychomycosis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Onychomycosis Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Onychomycosis, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Onychomycosis epidemiology in the 7MM

• Onychomycosis marketed and emerging therapies

• Onychomycosis companies

• Onychomycosis market drivers and barriers

Table of Contents:

1 Onychomycosis Market Key Comprehensive Insights

2 Onychomycosis Market Report Introduction

3 Competitive Intelligence Analysis for Onychomycosis

4 Onychomycosis Market Analysis Overview at a Glance

5 Executive Summary of Onychomycosis

6 Onychomycosis Epidemiology and Market Methodology

7 Onychomycosis Epidemiology and Patient Population

8 Onychomycosis Patient Journey

9 Onychomycosis Treatment Algorithm, Onychomycosis Current Treatment, and Medical Practices

10 Key Endpoints in Onychomycosis Clinical Trials

11 Onychomycosis Marketed Therapies

12 Onychomycosis Emerging Therapies

13 Onychomycosis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Onychomycosis

16 Onychomycosis Market Key Opinion Leaders Reviews

18 Onychomycosis Market Drivers

19 Onychomycosis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Onychomycosis Epidemiology 2034

DelveInsight’s “Onychomycosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Onychomycosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Onychomycosis Pipeline 2024

“Onychomycosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onychomycosis market. A detailed picture of the Onychomycosis pipeline landscape is provided, which includes the disease overview and Onychomycosis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Onychomycosis Market Expected to rise, 2034 | Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, expected to drive market